The purinergic environment in the TME can promote both antitumor immunity and cancer immune evasion, depending on the expression profiles of purinergic receptors and other components of the purinergic signaling system, such as ectoenzymes, which determine ATP and adenosine concentrations in the TME. The gene discussed is P2RX4; the disease is cancer.